CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Adalimumab PFS and Pendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02565810
NCT02565810Phase 2Completed

An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Samsung Bioepis Co., Ltd.·interventional·Posted Oct 1, 2015·Updated Apr 1, 2019

In Brief

A Phase 2 clinical trial evaluating Adalimumab PFS and Pen for Rheumatoid Arthritis. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 1, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.8 years ago

Interventions

Adalimumab PFS and Pendrug